Timber Pharmaceuticals Announces Adjournment of Annual Meeting
Timber Pharmaceuticals, Inc. (TMBR) announced that the 2021 Annual Meeting of Stockholders was convened without a quorum on June 3, 2021, leading to its adjournment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Timber Pharmaceuticals, Inc. (TMBR) announced that the 2021 Annual Meeting of Stockholders was convened without a quorum on June 3, 2021, leading to its adjournment. The meeting is rescheduled for July 1, 2021, at 1:00 p.m. ET, allowing shareholders more time to vote. The record date remains April 12, 2021. Timber Pharmaceuticals focuses on developing treatments for rare dermatologic diseases, including congenital ichthyosis and scleroderma.
Positive
- Company holds a focus on treatments for rare dermatologic diseases, which may attract niche market interest.
Negative
- The failure to establish a quorum could indicate shareholder disengagement or dissatisfaction.
Details
News Market Reaction – TMBR
The recorded move for TMBR in the trading session of this news was +0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 3, 2021 its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was convened without a quorum. As a result, in order to provide stockholders additional time within which to vote their eligible shares to establish a quorum, the Annual Meeting was adjourned.
The adjourned meeting will be held at 1:00 p.m. ET on Thursday, July 1, 2021 at the following url: www.virtualshareholdermeeting.com/TMBR2021. The record date for the Annual Meeting remains April 12, 2021.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.